Financial Results and Business Update
•Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint
•SUPRAME topline data disclosure remains expected in H1 2027, followed by BLA submission in 2027
•IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ESMO Congress 2026 showed deep and durable anti-tumor activity across multiple tumor types and a manageable safety profile; in gynecologic cancers at clinically relevant doses, cORR was 55% and mDOR was 8.4 months
•IMA402 PRAME Bispecific: Phase 1b data presented at ESMO Congress 2026 continue to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile, within the recommended Phase 2 dose (RP2D) range.